No wonder Valeant CEO Michael Pearson is so confident that he is closing in on enough support from investors to call a special meeting to oust a majority of Allergan's recalcitrant board. He only needs votes accounting for 25 per cent of Allergan stock. And at least 20 per cent is already in the hands of hedge funds, arbitrage types and other market players more interested in quick scores than the costly development of blockbuster drugs.